相关实验视频
Updated: May 28, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
980
在阿托皮性皮肤炎的老年患者中,以治疗到目标共识建议为指导的乌帕达西提尼布剂量减少方案
Zequn Tong1,2,3, Xueting Zeng1,2,3, Fuchen Huang1,2,3
1Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou, 350000, Fujian, China.
American journal of clinical dermatology
|February 12, 2025
概括
延长Janus激酶 (JAK) 抑制剂的剂量间隔对于患有亚托皮炎 (AD) 的老年人来说是有效和安全的. 这种方法以治疗到目标 (T2T) 原则为指导,可以持续控制疾病并减少不良事件.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 简氏激酶 (JAK) 抑制剂对亚托皮性皮肤炎 (AD) 有效.
- 在阿尔茨海默病的老年患者中,对JAK抑制剂的更长剂量间隔没有得到充分的研究.
- 老年患者有较高的 JAK 抑制剂不良事件的风险.
研究的目的:
- 为了评估延长JAK抑制剂剂量间隔在AD的老年人中的疗效和安全性.
- 评估是否可以通过较少的剂量保持疾病控制.
- 在这个人群中应用治疗到目标 (T2T) 共识来优化JAK抑制剂治疗.
主要方法:
- 预期观察队列研究 (2022年7月 - 2024年2月).
- 包括58名患有中度至重度AD的老年患者 (≥65岁).
- 患者接受了upadacitinib,剂量间隔逐渐延长,遵循T2T原则.
主要成果:
- 86.2%的患者完成了1年的随访.
- 在最后一次访问时,26.0%的人保持每3天服用一次,而72.0%的人保持每2天服用一次.
- 总体不良事件 (AEs) 为29.3%,其中疹病毒感染是最常见的 (13.8%).
结论:
- 通过T2T共识指导的延长间隔减少剂量,在老年阿尔茨海默病患者中耐受良好.
- 延长JAK抑制剂剂量间隔可以保持老年人的疾病控制.
- 长时间的间隔可以为患者和社会经济带来好处.
相关概念视频
01:11Renal Failure: Dose Adjustments
60
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
60
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141